Physician profile
Derek A Damin
NPI 1003809724
$43,855.11
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13K · 2021: $15K · 2022: $4,269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24,659.50 | 2019-2022 | |
| Grifols USA, LLC | $11,436.45 | 2019-2022 | |
| Genzyme Corporation | $3,061.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,096.31 | 2019-2022 | |
| Csl Behring | $1,017.11 | 2019-2022 | |
| Kaleo, INC. | $497.44 | 2019-2022 | |
| Pfizer INC. | $304.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $289.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.40 | 2020-2022 | |
| Shire North American Group INC | $254.35 | 2019 | |
| Optinose US, INC. | $184.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $122.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.88 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $108.27 | 2021 | |
| Pharming Healthcare, INC. | $77.50 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.92 | 2021-2022 | |
| Octapharma USA, INC. | $63.71 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $56.95 | 2020-2021 | |
| Alk-Abello, INC | $37.31 | 2020 | |
| Incyte Corporation | $33.07 | 2022 | |
| Aimmune Therapeutics, INC. | $20.57 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.06 | 2021 | |
| Abbvie INC. | $15.52 | 2022 | |
| Merck Sharp & Dohme LLC | $14.01 | 2022 | |
| Genentech USA, INC. | $12.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Damin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.